Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7976063 | 0.97 | TSHR (0.38) | TSHRALDH1A1RIPK1FKBP1AFFAR3 | |
| SCHEMBL553596 | 0.84 | TDP1 (0.38) | TSHRALDH1A1RIPK1FKBP1AFFAR3 | |
| SCHEMBL11000935 | 0.78 | TDP1 (0.40) | TSHRALDH1A1FFAR3CYP2C19TDP1 | |
| SCHEMBL8603741 | 0.77 | TDP1 (0.35) | TSHRALDH1A1RIPK1FKBP1ATDP1 | |
| SCHEMBL3917530 | 0.77 | FKBP1A (0.33) | TSHRRIPK1FKBP1ATDP1 | |
| SCHEMBL7195881 | 0.77 | RIPK1 (0.36) | TSHRALDH1A1RIPK1FFAR3HMGCR | |
| SCHEMBL7195884 | 0.77 | RIPK1 (0.36) | TSHRALDH1A1RIPK1FFAR3HMGCR | |
| SCHEMBL392087 | 0.77 | TSHR (0.40) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL4381836 | 0.77 | TSHR (0.40) | TSHRALDH1A1FFAR3HMGCRCHRM1 | |
| SCHEMBL9247690 | 0.77 | TSHR (0.40) | TSHRALDH1A1FFAR3HMGCRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125513-A1 | CURABLE RESIN COMPOSITIONS | ILLUMINA INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4405750-B1 | CURABLE RESIN COMPOSITIONS | ILLUMINA INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-12559627-B2 | Curable resin compositions | ILLUMINA, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4405750-A1 | CURABLE RESIN COMPOSITIONS | Illumina, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| EP-4405749-A2 | CURABLE RESIN COMPOSITIONS | Illumina, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| US-20230100285-A1 | CURABLE RESIN COMPOSITIONS | ILLUMINA, INC. | 2023-03-30 | — | — | US | claimed |
| WO-2023046814-A1 | CURABLE RESIN COMPOSITIONS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-03-30 | — | — | WO | claimed |
| WO-2023046813-A2 | CURABLE RESIN COMPOSITIONS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-03-30 | — | — | WO | claimed |
| CN-109563106-B | Silver ion carboxylate alkyl primary amine complexes | 柯达公司 | 2021-07-27 | — | — | CN | claimed |
| CN-109562628-B | Silver ion carboxylate N-heteroaromatic complex and use | 柯达公司 | 2021-07-27 | — | — | CN | claimed |
| US-9783553-B1 | Silver ion α-oxy carboxylate-oxime complexes | EASTMAN KODAK COMPANY (US) | 2017-10-10 | — | — | US | claimed |
| US-9718842-B1 | Silver ion carboxylate primary alkylamine complexes | EASTMAN KODAK COMPANY (US) | 2017-08-01 | — | — | US | claimed |
| US-9376694-B2 | Method for preparing optically active amino acid using cosubstrate shuttling of transaminase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-28 | — | — | US | claimed |
| US-20150284750-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ACID USING COSUBSTRATE SHUTTLING OF TRANSAMINASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-10-08 | — | — | US | claimed |
| EP-1635806-B1 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIV PITTSBURGH (US) | 2008-05-28 | — | — | EP | claimed |
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| US-5854035-A | Enzyme with leuDH activity, nucleotide sequence coding therefor and process for the prepartion of the enzyme | DEGUSSA AG (DE) | 1998-12-29 | — | — | US | claimed |
| EP-0792933-A2 | Enzyme having LeuDH activity, nucleotide sequence coding therefor and process for the preparation of this enzyme | Degussa Aktiengesellschaft (DE) | 1997-09-03 | — | — | EP | claimed |
| EP-0720531-B1 | MULTILAYER BARRIER FILM FOR OSTOMY APPLICATIONS | DOW CHEMICAL CO (US) | 1997-05-28 | — | — | EP | claimed |
| US-5468526-A | Multilayer barrier film for ostomy applications | THE DOW CHEMICAL COMPANY (US) | 1995-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559627-B2 | Curable resin compositions | PSMB2, ECPAS, RPS26 | TSHR 2781/4885ALDH1A1 3100/4885RIPK1 1449/4885 |
| US-20260125513-A1 | CURABLE RESIN COMPOSITIONS | RAD51, ACR, ACMSD | TSHR 3849/4885ALDH1A1 562/4885RIPK1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.